**To the Editor:**

We refer to a recently published article[@R1] that shows a new Bayesian method, applied to assess a vaccination strategy preventing human papillomavirus (HPV)-related diseases. The article basically describes a model for the economic evaluation of the quadrivalent HPV vaccine in Italy, concluding that it is a cost-effective strategy. Although any model, Bayesian or Frequentist, should be "populated" with reliable data,[@R2] we felt some concern about many "inputs" regarding the Italian setting that could weaken the authors' conclusions. We have listed some of the main ones.

-   Real data on Italian vaccination coverage are referenced by an abstract,[@R3] without specifying that this refers to a very small region in Italy (Basilicata, 0.97% of the whole Italian population). Thereafter, table 1 refers for vaccination compliance and coverage to another article, published in Italian, focussed on the efficacy of the quadrivalent vaccine.[@R4]

-   Data on health states associated with HPV-related diseases refer to another abstract,[@R5] then unspecified Italian utility weights for health states were applied, but to our knowledge, no utility tariffs have been validated so far in Italy.

-   Utilities of cervical cancer, genital and cervical lesions, all refer to an article on the costs of varicella-related hospitalizations in table 1.[@R6]

-   The vaccine price is not consistent with published data,[@R7] and we could not find the figure used as a mean (€69.13, see table 1) in the references.[@R8],[@R9]

More in general, the authors state that the cost-effectiveness of the quadrivalent vaccine is proven, ignoring the other, bivalent vaccine against HPV. As 3 recent critical reviews[@R10]--[@R12] on economic evaluations regarding HPV vaccines---not cited in the article---concluded that long-term models on HPV vaccination lack transparency in key assumptions and methodological choices, we wonder whether the results of this model (producing a "virtual" follow-up of 90 y) can really be considered more reliable than the others already published.
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